Semaglutide: Clinical Guide for Prescribing Practices
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and subsequently approved for chronic weight management (Wegovy). Compounded semaglutide is widely prescribed in clinical practice for weight loss programs. It is one of the highest-demand compounded medications in the US and represents a core revenue driver for practices offering medical weight management.
Also Known As
How Semaglutide Works
Semaglutide is a modified GLP-1 analog with 94% homology to native GLP-1, engineered with a C-18 fatty acid chain that enables albumin binding and extends half-life to approximately 7 days. It activates GLP-1 receptors in the hypothalamus to reduce appetite, in the pancreas to enhance glucose-dependent insulin secretion, and in the GI tract to delay gastric emptying [1]. The net effect is sustained caloric reduction, improved glycemic control, and progressive weight loss.
Clinical Evidence
The STEP 1 trial demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4mg weekly versus 2.4% with placebo [2]. The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events in overweight/obese patients without diabetes [3]. Semaglutide received FDA approval for chronic weight management (Wegovy) in June 2021 based on this evidence [1]. Real-world data from clinical practice settings confirms similar efficacy when combined with lifestyle modification programs.
Clinical Uses
Patient Selection and Screening
Ideal candidates have BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea) [1]. Screen for personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (absolute contraindication). Evaluate for history of pancreatitis, gallbladder disease, and eating disorders before initiation. Patients should understand this is a long-term therapy with potential for weight regain upon discontinuation [2].
Dosing and Administration
Standard titration per FDA labeling: 0.25mg weekly for 4 weeks, then 0.5mg for 4 weeks, then 1.0mg for 4 weeks, then 1.7mg for 4 weeks, then 2.4mg maintenance [1]. Compounded versions may use different concentrations; adjust volume accordingly [4]. Some clinicians use slower titration (6-8 week intervals) for patients with significant GI sensitivity. Treatment duration is indefinite for weight maintenance; clinical judgment should guide discontinuation planning.
Route: Subcutaneous injection
Protocol notes: Administered via weekly subcutaneous injection with dose titration over 4-8 weeks to minimize GI side effects. Starting dose is typically 0.25mg weekly, titrated to maintenance dose.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Semaglutide weight loss programs represent the highest-revenue peptide offering for most practices, with monthly patient spend ranging from $300-600 for compounded formulations [4]. Programs structured with intake labs, monthly follow-ups, and dietary counseling can generate $3,000-6,000 per patient annually. Market demand remains exceptionally high, making this a primary patient acquisition driver.
FDA Category Status
Compounding eligibility tied to FDA drug shortage status; verify current classification before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Semaglutide through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the difference between branded and compounded semaglutide?
How should practices structure semaglutide weight loss programs?
What are the key compliance considerations for prescribing compounded semaglutide?
References
- FDA Approval of Wegovy (semaglutide 2.4mg) for Chronic Weight Management
- Wilding et al. - Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021)
- Lincoff et al. - Semaglutide and Cardiovascular Outcomes in Obesity (SELECT Trial, NEJM 2023)
- FDA Compounding and Drug Shortage Information
Related Peptides in Weight Loss & Metabolic
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Semaglutide Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Semaglutide Through Karpa